S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy's premier visits Libya for talks on energy, migration
Is This The End of Capitalism? (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
Is This The End of Capitalism? (Ad)
Challenge for Tunisian democracy: Getting voters to show up
Is tipping getting out of control? Many consumers say yes
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy's premier visits Libya for talks on energy, migration
Is This The End of Capitalism? (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
Is This The End of Capitalism? (Ad)
Challenge for Tunisian democracy: Getting voters to show up
Is tipping getting out of control? Many consumers say yes
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy's premier visits Libya for talks on energy, migration
Is This The End of Capitalism? (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
Is This The End of Capitalism? (Ad)
Challenge for Tunisian democracy: Getting voters to show up
Is tipping getting out of control? Many consumers say yes
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy's premier visits Libya for talks on energy, migration
Is This The End of Capitalism? (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
Is This The End of Capitalism? (Ad)
Challenge for Tunisian democracy: Getting voters to show up
Is tipping getting out of control? Many consumers say yes
OTCMKTS:CNBX

CNBX Pharmaceuticals - CNBX Stock Forecast, Price & News

$0.53
-0.07 (-11.76%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.53
▼
$0.55
50-Day Range
$0.53
▼
$4.00
52-Week Range
$0.53
▼
$12.42
Volume
5,812 shs
Average Volume
11,769 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CNBX stock logo

About CNBX Pharmaceuticals (OTCMKTS:CNBX) Stock

CNBX Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of cannabinoid-based treatments and therapies for cancer. Its lead product candidate is RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer. In addition, it develops Cannabics SR, a lipid-based capsule containing a standardized formulation of cannabinoids for the treatment of cancer anorexia-cachexia syndrome; and Cannabics CDx, an ex-vivo drug sensitivity test. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. CNBX Pharmaceuticals Inc. is a subsidiary of Cannabics Inc.

Receive CNBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CNBX Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CNBX Stock News Headlines

November 8, 2022 | benzinga.com
CNBX Acquires A Controlling Interest In Cancer Immunotherapy Developer
November 8, 2022 | finance.yahoo.com
CNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza Biopharma
January 29, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
October 18, 2022 | finance.yahoo.com
CNBX Files New PCT Patent Application For Cannabinoids-Based Neoadjuvant Cancer Therapy
October 13, 2022 | finance.yahoo.com
CNBX Patent Application "Composition and Method for Treating Cancer with Cannabinoids" Enters National Phase in US and Israel
September 28, 2022 | finance.yahoo.com
CNBX Pharmaceuticals Announces New Patent Granted in Australia
September 12, 2022 | reuters.com
CNBX Pharmaceuticals Inc
August 16, 2022 | ca.finance.yahoo.com
CNBX Pharmaceuticals Inc. (CNBX)
January 29, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
June 10, 2022 | benzinga.com
CNBX Pharmaceuticals (OTC:CNBXD), Earnings Estimates, EPS, and Revenue
June 10, 2022 | benzinga.com
CNBX Pharmaceuticals (OTC:CNBXD), Analyst Ratings, Price Targets, Predictions
June 7, 2022 | finance.yahoo.com
CNBX Pharmaceuticals Inc. (CNBXD)
May 31, 2022 | finance.yahoo.com
CNBX Pharmaceuticals Release a New Corporate Presentation
May 14, 2022 | barrons.com
CNBX Pharmaceuticals Inc.
May 5, 2022 | seekingalpha.com
CNBX pharma granted patent in Hong Kong for cancer therapy
May 5, 2022 | finance.yahoo.com
CNBX Pharmaceuticals Granted Patent in Hong Kong
April 4, 2022 | msn.com
Novartis to save at least $1 billion by 2024 thanks to simplified structure
April 4, 2022 | msn.com
Vertex Pharma sees positive results in Phase 2 trials of new non-opioid pain killer
April 4, 2022 | cnbc.com
What to watch today: Wall Street looks higher; Twitter soars on Elon Musk stake
April 4, 2022 | msn.com
Stocks making the biggest moves in the premarket: Twitter, Tesla, Starbucks and more
April 1, 2022 | cnbc.com
CNBC Transcript: Johnson & Johnson CEO Joaquin Duato Speaks with CNBC’s Meg Tirrell Live During CNBC’s Healthy Returns Summit Today
April 1, 2022 | cnbc.com
What to watch today: Wall Street set to wrap up strong month but weak quarter
April 1, 2022 | msn.com
Stocks making the biggest moves premarket: Walgreens, Baidu, Novavax and others
April 1, 2022 | msn.com
Vertex Pharmaceuticals reports positive data on non-opioid pain medicine
March 28, 2022 | finance.yahoo.com
Cannabics Pharmaceuticals Changes Name to CNBX Pharmaceuticals
November 30, 2021 | benzinga.com
Avicanna To Bring Its Cannabinoid-Based Drugs To Argentina Via 'Established' Pharma Partner
November 4, 2021 | finance.yahoo.com
CNBX Selects API Supplier Purisys to Support Planned IND Fillings and Phase I/II (a) Clinical Trials
See More Headlines
Receive CNBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CNBX Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Biotechnology
Sub-Industry
Cannabis
Sector
Medical
Current Symbol
OTCMKTS:CNBX
CUSIP
N/A
CIK
1343009
Web
www.cannabics.com
Phone
(877) 424-2429
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Gabriel Yariv (Age 47)
    Pres, COO & Exec. Chairman
    Comp: $261.93k
  • Mr. Eyal Barad (Age 58)
    Co-Founder, CEO & Director
    Comp: $269.15k
  • Mr. Uri Ben-Or CPA (Age 53)
    CPA, M.B.A., MBA, Chief Financial Officer
    Comp: $75.32k
  • Dr. Sanja Goldberg (Age 47)
    Chief Technology Officer
    Comp: $48.12k
  • Noam Permont
    VP of PR & Investor Relations
  • Dr. Sigalit Ariely-Portnoy Ph.D. (Age 59)
    Sr. Advisor of Regulation, Validation & Quality and Member of Advisory Board
  • Dr. Tal Mofkadi Ph.D.
    Financial Advisor & Member of Advisory Board
  • Mr. Yasha Borstein (Age 60)
    Chief Data Officer
  • Dr. Yaakov Waksman (Age 71)
    Head of Cannabidiol Research
  • Dr. Ilya Reznik M.D.
    Head of Neuropsychiatry Devel.

Key Competitors

View All Competitors













CNBX Stock - Frequently Asked Questions

How have CNBX shares performed in 2023?

CNBX Pharmaceuticals' stock was trading at $1.86 at the start of the year. Since then, CNBX stock has decreased by 71.8% and is now trading at $0.5251.
View the best growth stocks for 2023 here.

When did CNBX Pharmaceuticals' stock split?

CNBX Pharmaceuticals shares reverse split on Thursday, May 12th 2022. The 1-120 reverse split was announced on Thursday, May 12th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 12th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What other stocks do shareholders of CNBX Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CNBX Pharmaceuticals investors own include Gran Tierra Energy (GTE), Organigram (OGI), KushCo (KSHB), Pennsylvania Real Estate Investment Trust (PEI), Medical Marijuana (MJNA), Auxly Cannabis Group (CBWTF), American Cannabis (AMMJ), GreenGro Technologies (GRNH), MassRoots (MSRT) and Surna (SRNA).

What is CNBX Pharmaceuticals' stock symbol?

CNBX Pharmaceuticals trades on the OTCMKTS under the ticker symbol "CNBX."

How do I buy shares of CNBX Pharmaceuticals?

Shares of CNBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CNBX Pharmaceuticals' stock price today?

One share of CNBX stock can currently be purchased for approximately $0.53.

How can I contact CNBX Pharmaceuticals?

CNBX Pharmaceuticals' mailing address is #3 Bethesda Metro Center, Suite 700, BETHESDA, MD 20814, United States. The official website for the company is www.cannabics.com. The company can be reached via phone at (877) 424-2429.

This page (OTCMKTS:CNBX) was last updated on 1/29/2023 by MarketBeat.com Staff